RARE241220C45000
- 11.96
- 0.000.00%
Ultragenyx Pharmaceutical Newsroom
Insider Sale: President & CEO of $RARE (RARE) Sells 8,273 Shares
TD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Mereo Stock Gains as Jefferies Starts Coverage With Buy Rating
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Business And Shares Still Trailing The Industry
Ultragenyx to Participate in Investor Conferences in December
Ultragenyx Pharmaceutical Analyst Ratings
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $102
Express News | Ultragenyx Pharmaceutical Inc : JP Morgan Cuts Target Price to $102 From $105
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $121
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Posts Trial Data Backing Phase 3 Design for Angelman Syndrome Therapy
Express News | Ultragenyx Presents Positive Update on Gtx-102 Angelman Syndrome Program at Fast’s 17TH Annual Global Science Summit
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates